| Document |
Document Title |
|
WO/2018/053157A1 |
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a pat...
|
|
WO/2018/041768A1 |
The invention relates to novel organic semiconducting (OSC) compounds containing one or more 1,3-dithiolo[5,6-f]benzo-2,1,3-thiadiazole ("DTBTz") or 1,3-dithiolo[6,7-g]quinoxaline ("DTQ") units or derivatives thereof, to methods for thei...
|
|
WO/2018/035005A1 |
The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3 and R5 are as defined herein. The present invention also relates...
|
|
WO/2018/034977A1 |
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula or a pharmaceutically acceptab...
|
|
WO/2018/033086A1 |
Disclosed are a compound having xanthone as the core and applications thereof in an organic electroluminescent component. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking m...
|
|
WO/2018/031334A1 |
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
|
|
WO/2018/021447A1 |
The purpose of the present invention is to provide a novel compound having D3 receptor antagonistic effect. Provided are the following: a compound represented by formula (I) (in the formula, ring A is a heterocyclic ring, X1 groups are e...
|
|
WO/2018/020474A1 |
Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also di...
|
|
WO/2018/019297A1 |
Disclosed is an isoquinolinone compound as shown in formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation thereof and a use thereof in the preparation of drugs for treating or prev...
|
|
WO/2018/017435A1 |
The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or ...
|
|
WO/2018/013770A1 |
Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibi...
|
|
WO/2018/013774A1 |
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted...
|
|
WO/2018/011414A1 |
Derivatives of 1,2,4-Triazolo-[3,4-b]-1,3,4-thiadiazoles according to formula (I), processes for their production, pharmaceutical compositions containing them and their use in the treatment of cancer.
|
|
WO/2018/011163A1 |
The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prop...
|
|
WO/2018/011823A1 |
Disclosed are compounds and methods for the preparation of Edoxaban. In particular, a camphor sulfonate salt of an amine-protected [(1R,2S,5S)-1,2-amino-5-[(dimethylamino)carbonyl] cyclohexane, an intermediate that may be formed in the s...
|
|
WO/2018/007479A1 |
The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to...
|
|
WO/2018/007957A1 |
The present invention refers to novel thiazolo[5,4-d]pyrimidine derivatives that are inverse agonists of the adenosine A2A receptor, to a process for their preparation, to the pharmaceutical compositions containing them and to their use ...
|
|
WO/2018/008984A1 |
The present invention relates to a pharmaceutical composition for preventing or treating pulmonary hypertension, the composition comprising: an epidithiodioxopiperazine (ETP) compound or a derivative thereof; or a pharmaceutically accept...
|
|
WO/2018/008920A1 |
Provided is a pharmaceutical composition for preventing and treating tumors, the pharmaceutical composition including an imidazooxazole derivative compound, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof as an a...
|
|
WO/2018/007843A1 |
The compound 2-((4-Nitrophenyl)amino)-7,8,9,10-tetrahydrocyclohepta[4,5]t
hieno[2,3-d][1,3,4]thiadiazolo[3,2-a]pyrimidin-11(6H)-one and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation ...
|
|
WO/2018/002437A1 |
Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.
|
|
WO/2018/003976A1 |
In agricultural and horticultural crop production, etc., damage by pests and the like remains devastating even today, and due to factors such as the occurrence of pests resistant to existing chemicals, there is a demand for the developme...
|
|
WO/2017/222976A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2017/220925A1 |
The invention relates to a method for preparing substituted thiolactones of formula (I), new substituted thiolactones of formula (I') that can be obtained by carrying out said method, and the use of substituted thiolactones of formula (I...
|
|
WO/2017/220477A1 |
The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as ...
|
|
WO/2017/222466A1 |
The present invention relates to heterocyclic compounds of Formula I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compo...
|
|
WO/2017/223474A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2017/216281A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2017/216706A1 |
The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation...
|
|
WO/2017/216283A1 |
The present invention relates to the following compounds, formula (I), wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2017/211759A1 |
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.
|
|
WO/2017/211760A1 |
The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L1-Y-L2-R-B, wherein A is a cyclic group havin...
|
|
WO/2017/214005A1 |
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.
|
|
WO/2017/207395A1 |
The present invention relates to novel isothiazolopyridones (isothiazolopyridone derivatives), to processes for preparing these compounds, to compositions comprising these isothiazolopyridones, and to the use thereof as biologically acti...
|
|
WO/2017/207462A1 |
The invention relates to the technical field of the herbicides and/or plant growth regulators. Specifically, the invention primarily relates to novel isothiazolopyridones, and compositions comprising said novel isothiazolopyridones. Furt...
|
|
WO/2017/207387A1 |
The present invention covers diazaspiroalkylmethyl-indole compounds of general formula (I) in which R8, X and Y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharm...
|
|
WO/2017/201069A1 |
The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell ad...
|
|
WO/2017/195112A1 |
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...
|
|
WO/2017/190345A1 |
Provided is the design, synthesis and applications of molecular fluorophores for bioimaging in the short wavelength infrared window (1000-1700 nm). The molecular fluorophores compound comprise structures with electron accepting aromatic ...
|
|
WO/2017/192930A1 |
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...
|
|
WO/2017/192961A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2017/177828A1 |
The present invention relates to a novel oxazolidinone-fluoroquinolone derivative and uses, and relates to the field of chemical drugs. The present invention also relates to a compound represented by formula (I), a pharmaceutically accep...
|
|
WO/2017/177837A1 |
The present invention relates to a heterocyclic-substituted pyridinopyrimidinone derivative, and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present invention relates to the ...
|
|
WO/2017/175068A1 |
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
|
|
WO/2017/173313A1 |
Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.
|
|
WO/2017/170759A1 |
Provided is a novel herbicide having a significant herbicidal activity against undesirable plants. A pyridazinone-type compound represented by general formula (I) (wherein X represents -O-, -S-, -SO-, -SO2- or -N(Y)-; Q represents a mono...
|
|
WO/2017/157782A1 |
The invention relates to novel compounds containing one or more benzo[1,2-d;4,5-d']bisthiazole-4,8-diyl ("BBT") units, to methods for their preparation and educts or intermediates used therein, to mixtures and formulations containing the...
|
|
WO/2017/160552A1 |
Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic too...
|
|
WO/2017/160555A1 |
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically accepta...
|
|
WO/2017/153601A1 |
The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synucl...
|
